



# Predictors of Mortality in critically ill patients with COVID-19 infection on mechanical ventilation

Victor Perez-Gutierrez MD, Bo Yu MD, Alex Carlos MD, Shazia Aziz MD, Mohammad Aldiabat MD, Sara Tavarez MD, Shekar Murthy MD, Vidya Menon MD, FACP  
Department of Internal Medicine, NYC + HHC, Lincoln




## BACKGROUND

On March, New York was declared in "State of Emergency"; all Emergency Room and hospital facilities in NYC were overwhelmed by the rapid and high influx of patients with COVID-19 infection. At least 20% of patients with criteria for hospitalization received mechanical ventilation, and the Mortality reached 80% in a time when the only treatment option was oxygen support. South Bronx has a different population compared with other Boroughs in NYC. Disparities as income inequality, housing issue, and high comorbidities prevalence make this population unique to assess the clinical course and outcomes (1,2). We aimed to evaluate baseline characteristics and clinical features as predictors of mortality in mechanically ventilated patients due to COVID-19 infection.

## METHODS

The retrospective cohort study included SARS-CoV2 positive patients by RT-PCR that underwent mechanical intubation during their hospital course between March-May 2020. Death in less than 24 hours after endotracheal intubation, patient intubated in the field, or transferred intubated from other facilities to our hospital were part of the exclusion criteria (figure 1). Simple logistic regression was performed to recognize variables for our model and Multiple logistic regression to identify covariates and cofounders for Mortality. A significant *p-value* was considered as <0.05. IBM SPSS v22 for Windows was used for analysis.

Figure 1. Flow diagram of process for patient inclusion as participant of the study




## RESULTS

**Table 1: Univariate analysis for mortality in mechanically ventilated patient due to COVID-19 infection**

| Variable  | Death (n=274), n(%) | Alive (n=80), n(%) | OR (95% CI)      | p-value |
|---|---------------------|--------------------|------------------|---------|
| Age (>60 years-old)   | 109 (39.8%)         | 31 (37.0%)         | 1.39 (1.43-2.98) | 0.001   |
| Female  | 110 (38%)           | 32 (39%)           | 1.09 (0.65-1.83) | 0.737   |
| Race  |                     |                    | Reference        |         |
| Non-LatinX  | 86 (31.4%)          | 23 (28.7%)         |                  |         |
| LatinX  | 188 (68.6%)         | 57 (71.3%)         | 1.13 (0.85-1.96) | 0.653   |
| BMI* (>30 kg/m <sup>2</sup> )   | 153 (55.8%)         | 44 (55.0%)         | 1.03 (0.62-1.70) | 0.894   |
| Hypertension  | 129 (47.1%)         | 32(40.0%)          | 1.33 (0.80-2.21) | 0.234   |
| Diabetes  | 133 (48.5%)         | 29 (36.3%)         | 1.65 (0.99-2.77) | 0.053   |
| Obstructive lung disease  | 56 (20.4%)          | 10 (12.5%)         | 1.79 (0.87-3.71) | 0.113   |
| Chronic kidney disease  | 39 (14.2%)          | 6 (7.5%)           | 2.04 (0.83-5.02) | 0.116   |
| COVID severity  |                     |                    | Reference        |         |
| Moderate  | 16 (5.8%)           | 13 (16.3%)         |                  |         |
| Severe  | 87 (31.8%)          | 29(36.8%)          | 2.43 (1.04-5.66) | 0.039   |
| Critical  | 171 (62.4%)         | 38 (47.5%)         | 3.65 (1.62-8.23) | 0.002   |
| Sepsis*   | 183 (66.8%)         | 33 (41.3%)         | 2.86 (1.71-4.77) | 0.000   |
| Acute kidney injury   | 191 (69.7%)         | 34 (42.5%)         | 3.11 (1.86-5.19) | 0.000   |
| ARDS* on admission  | 171 (62.4%)         | 38 (47.5%)         | 1.83 (1.11-3.03) | 0.018   |
| Vasopressor during the hospital course                                      | 230 (83.9%)         | 53 (66.3%)         | 2.66 (1.51-4.68) | 0.001   |
| APACHE score (>18)  | 115 (42.0%)         | 26 (32.5%)         | 1.50 (0.88-2.54) | 0.129   |
| ARDS Protocol   | 31 (11.3%)          | 16 (20.0%)         | 0.51 (0.26-0.99) | 0.047   |
| Tidal volume by IBW*  | 49 (17.9%)          | 20 (25.0%)         | 0.85(0.36-1.18)  | 0.159   |
| Hydroxychloroquine  | 239 (87.2%)         | 73 (97.3%)         | 0.65 (0.27-1.53) | 0.330   |
| Therapeutic anticoagulation   | 102 (37.2%)         | 33 (41.3%)         | 0.84 (0.50-1.40) | 0.515   |
| Steroids stress dose  | 77 (28.1%)          | 25 (31.3%)         | 0.86 (0.50-1.47) | 0.585   |
| Prone by protocol   | 74 (27.0%)          | 19 (23.8%)         | 1.18 (0.66-2.12) | 0.561   |
| WBC count during hospital course (> 18x10 <sup>3</sup> microliter)          | 138 (50.4%)         | 34 (42.5%)         | 1.37 (0.83-2.26) | 0.217   |
| Hemoglobin during hospital course (< 9 gr/dL)                               | 128 (46.7%)         | 43 (53.8%)         | 0.75 (0.45-1.24) | 0.269   |
| Platelet count during hospital course (<200x10 <sup>3</sup> per microliter) | 137 (50.0%)         | 27 (33.8%)         | 1.96 (1.16-3.30) | 0.011   |
| Creatinine during hospital course (>4 mg/deciliter)                         | 168 (61.3%)         | 19 (23.8%)         | 5.0 (2.87-8.99)  | 0.000   |

\*BMI, body mass index; ARDS, acute respiratory distress syndrome; MV, mechanical ventilation; IBW, ideal body weight; Sepsis defined by Quick SOFA score.

Table 2: MULTIVARIATE ANALYSIS FOR PREDICTORS OF MORTALITY



## CONCLUSION

Mortality in mechanically ventilated patients in our cohort was 82% and did not differ from other studies in NYC (3). The WHO guidelines recommend mechanical ventilation support in COVID-19 infection for patients in ARDS or need support for other dysfunctional organs. Older age, AKI, ARDS, and degree of oxygen support are independent predictors of Mortality in critically ill patients with COVID-19 infection. SARS CoV-2 produces diffuse alveolar damage in the lungs that lead the patient toward ARDS. Therefore, ARDS protocol shows benefit in preventing Mortality among critically ill patients with COVID-19. This intervention assures enough oxygen levels in lungs with poor compliance. It seems to be the only measure that improves Mortality among Mechanically Ventilated patients with COVID-19 infection (4-6).

## IMPLICATIONS

Identification of predictors of mortality in Mechanically ventilated patients with COVID-19 will be a valuable tool to promptly redirect resources in order to prevent fatalities.

## REFERENCES

- Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med.* 2020;382(10):929-936. doi:10.1056/NEJMoa2001191
- Uppal A, Silvestri DM, Siegler M, et al. Critical Care And Emergency Department Response At The Epicenter Of The COVID-19 Pandemic. *Health Aff (Millwood).* 2020;39(8):1443-1449. doi:10.1377/hlthaff.2020.00901
- Shady A, Singh AP, Gbaje E, et al. Characterization of Patients with COVID-19 Admitted to a Community Hospital of East Harlem in New York City. *Cureus.* 2020;12(8):e9836. doi:10.7759/cureus.9836
- Xu, J., Yang, X., Yang, L. et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. *Crit Care* 24, 394 (2020)
- Navas-Blanco JR, Dudaryk R. Management of Respiratory Distress Syndrome due to COVID-19 infection. *BMC Anesthesiol.* 2020;20(1):177. Published 2020 Jul 20. doi:10.1186/s12871-020-01095-7
- Navas-Blanco JR, Dudaryk R. Management of Respiratory Distress Syndrome due to COVID-19 infection. *BMC Anesthesiol.* 2020 Jul 20;20(1):177. doi: 10.1186/s12871-020-01095-7. PMID: 32689937; PMCID: PMC7369540